Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00715143
Other study ID # CR05-005
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 2008
Est. completion date February 22, 2021

Study information

Verified date February 2015
Source Exactech
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to collect and evaluate long-term safety and effectiveness data on the Exactech® NOVATION ™ Ceramic Articulation Hip System ("NOVATION ™ Ceramic AHS").


Description:

The purpose of this study is to collect and evaluate long-term safety and effectiveness data on the Exactech® NOVATION ™ Ceramic Articulation Hip System ("NOVATION ™ Ceramic AHS"). Ten (10) years of follow-up data will be collected in this study. The first five (5) years of subject follow-up will involve clinical (Harris Hip Score, adverse events), radiographic, and self-assessment evaluation. The remaining five (5) years of subject follow-up will be accomplished with an outcomes questionnaire that will be completed by the subjects to evaluate the survivorship status of their hip replacement.


Recruitment information / eligibility

Status Terminated
Enrollment 126
Est. completion date February 22, 2021
Est. primary completion date February 22, 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria 1. Patient is undergoing primary hip surgery for symptomatic Non-inflammatory Degenerative Joint Disease (NIDJD). Composite diagnosis of NIDJD includes osteo/ degenerative arthritis, traumatic arthritis, congenital hip dysplasia and avascular necrosis. 2. Patient is 21 years of age or older at the time of surgery. 3. Patient is skeletally mature (tibial and femoral epiphyses are closed). 4. Patient is willing and able to return for follow-up as specified by the study protocol over a ten (10) year post-operative follow-up period; including 5 years of in-clinic visits followed by 5 years of mail-in questionnaire follow-up. 5. Patient is female and of childbearing age, for whom a negative urine pregnancy test is obtained immediately prior to surgery. 6. Patient does not meet any of the Exclusion Criteria. 7. Patient agrees to participate and sign the Informed Consent Form. Exclusion Criteria 1. Patient will be less than 21 years old at the time of surgery. 2. Patient is skeletally immature. 3. Patient presents with inflammatory degenerative joint disease. 4. Patient has evidence of active infection, but not including asymptomatic urinary tract infection (UTI) if treated with antibiotics preoperatively. 5. Patient is female and of child bearing age and is pregnant or whose pregnancy status is unknown. 6. Patient has neurological or musculoskeletal disease that may adversely affect gait or weight bearing. 7. Patient has known presence of active metastatic or neoplastic disease (active is defined as within the past 5 years. Does not include basal cell carcinoma in cases when a subject with this diagnosis has undergone radical excision of the lesion, has pathological proof that the lesion has clean and clear peripheral and deep borders, and the location of the lesion is not near the operative hip or on the affected extremity). 8. Patient has poor bone quality (e.g., osteoporosis) where, in the investigator's opinion, there is inadequate bone to support the implant(s). 9. Patient has the presence of a previous prosthetic hip replacement device (any type, including THA, surface replacement arthroplasty, endoprosthesis, etc.) in the operative hip joint. 10. Patient is known to have presence of a highly communicable disease or diseases that may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.). 11. Patient is a prisoner. 12. Patient is obese where obesity is defined as a Body Mass Index (BMI) greater than 35. BMI = Weight (lbs.) ÷ Height (in.)2 x 703 13. Patient has neuropathic joints. 14. Patient has known allergies to the implant materials. 15. Patient is unwilling or unable to comply with postoperative rehabilitation instructions and weight bearing limitations. 16. Patient's life expectancy is < 5 years due to chronic diseases such as cancer, congestive heart failure, etc. 17. Patient is unwilling or unable (e.g. cases of reduced mental capacity) to return for follow-up as specified by the study protocol over a ten (10) year post-operative follow-up period. 18. Patient has reduced mental capability (permanent or temporary) that would prevent following pre-surgical and post-surgical instructions. 19. Patient otherwise meets the study criteria but refuses to consent in writing to participate in the study.

Study Design


Related Conditions & MeSH terms

  • Total Hip Replacement (Non-inflammatory)

Intervention

Device:
Novation Ceramic
This treatment is the study device (which will be compared to a similar historic control device)

Locations

Country Name City State
United States Resurgens Orthopaedics Cumming Georgia
United States Shrock Orthopedic Research Fort Lauderdale Florida
United States Hampton Roads Orthopaedics & Sports Medicine Newport News Virginia
United States Tulsa Bone & Joint Associates Tulsa Oklahoma
United States Fallon Clinic Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Exactech

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Radiographic evaluation of radiolucency Radiographic analysis Immediately post operation, 6 weeks, 6 months, annually 1-5 years
Primary Survivorship of device components Device Survivorship Immediately post operation, 6 weeks, 6 months, annually 1-5 years
Primary Harris Hip Score Physician assessed outcome Immediately post operation, 6 weeks, 6 months, annually 1-5 years